Table 4.
Adverse events of NAC and CRT
| No. (%) | |
|---|---|
| Grade of NAC adverse events | 59 |
| Grade 1 | 13 (22.0) |
| Bone marrow hypocellular | 6 (10.2) |
| Gastrointestinal disorders | 6 (10.2) |
| Acute kidney injury | 1 (1.7) |
| ALT elevation | 1 (1.7) |
| Grade 2 | 34 (57.6) |
| Bone marrow hypocellular | 23 (39.0) |
| Gastrointestinal disorders | 13 (22.0) |
| Grade 3 | 5 (8.5) |
| Bone marrow hypocellular | 3 (6.8) |
| Gastrointestinal disorders | 2 (1.7) |
| Grade 4 | 1 (1.7) |
| Acute coronary syndrome | 1 (1.7) |
| Total grade 1–2 | 47 (79.6) |
| Total grade 3–4 | 6 (10.2) |
| Grade of CRT adverse events | 25 |
| Grade 1 | 5 (20.0) |
| Gastrointestinal disorders | 5 (20.0) |
| Skin rash | 2 (8.0) |
| Rectitis | 2 (8.0) |
| Grade 2 | 2 (8.0) |
| Gastrointestinal disorders | 2 (8.0) |
| Total grade 1–2 | 7 (28.0) |
ALT, alanine aminotransferase; CRT, chemoradiotherapy; NAC, neoadjuvant chemotherapy.